AngioDynamics (ANGO) Tops Q3 EPS by 4c; Adjusted FY17 Revs Lower, EPS Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
AngioDynamics Reports Fiscal 2017 Third Quarter Results
March 30, 2017 6:00 AM EDTQ3 net sales of $85.6 million, down 2% year-over-yearQ3 GAAP earnings per share of $0.08; non-GAAP adjusted EPS up 27% from Q3 fiscal 2016 Q3 operating cash generation of $14.4 million; free cash flow generation of $14.0 millionRevised FY2017 revenue and adjusted EPS guidance; free cash flow guidance unchanged
ALBANY, N.Y., March 30, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported financial results for the 2017 fiscal year third quarter... More
